Neogenomics, Inc.
NEO
$10.10
-$0.44-4.18%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 660.57M | 644.12M | 628.25M | 610.66M | 591.64M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 660.57M | 644.12M | 628.25M | 610.66M | 591.64M |
| Cost of Revenue | 370.47M | 363.69M | 360.39M | 355.40M | 347.04M |
| Gross Profit | 290.10M | 280.43M | 267.86M | 255.26M | 244.60M |
| SG&A Expenses | 337.48M | 329.91M | 327.74M | 321.94M | 313.73M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 739.10M | 723.92M | 716.04M | 704.88M | 688.08M |
| Operating Income | -78.54M | -79.80M | -87.79M | -94.22M | -96.44M |
| Income Before Tax | -80.68M | -79.83M | -83.44M | -91.06M | -97.10M |
| Income Tax Expenses | -1.95M | -2.11M | -4.89M | -6.82M | -9.13M |
| Earnings from Continuing Operations | -78.73 | -77.73 | -78.55 | -84.23 | -87.97 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -78.73M | -77.73M | -78.55M | -84.23M | -87.97M |
| EBIT | -78.54M | -79.80M | -87.79M | -94.22M | -96.44M |
| EBITDA | -5.99M | -7.08M | -14.93M | -21.20M | -23.85M |
| EPS Basic | -0.62 | -0.62 | -0.62 | -0.67 | -0.70 |
| Normalized Basic EPS | -0.33 | -0.33 | -0.38 | -0.41 | -0.43 |
| EPS Diluted | -0.63 | -0.62 | -0.63 | -0.67 | -0.71 |
| Normalized Diluted EPS | -0.33 | -0.33 | -0.38 | -0.41 | -0.43 |
| Average Basic Shares Outstanding | 506.63M | 505.40M | 504.13M | 503.08M | 502.00M |
| Average Diluted Shares Outstanding | 506.63M | 505.40M | 504.13M | 503.08M | 502.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
